A Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 Planned initiation date changed from 1 Mar 2016 to 1 Apr 2016.